<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02144636</url>
  </required_header>
  <id_info>
    <org_study_id>herbalife.2014</org_study_id>
    <nct_id>NCT02144636</nct_id>
  </id_info>
  <brief_title>Protein Supplementation and Weight Loss</brief_title>
  <official_title>Effect of Protein Supplementation on Weight Loss and Cardio Metabolic Profile of Overweight/Obese Subjects</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Diabetes Foundation, India</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Diabetes Foundation, India</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This randomized control trial of diet with protein supplementation is being conducted to test
      the hypothesis that in overweight/obese subjects high protein diet may lead to weight loss
      and improvement in cardio-metabolic profile.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>November 2012</start_date>
  <primary_completion_date type="Actual">October 2014</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>weight loss</measure>
    <time_frame>baseline to 3 months</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>improvement in lipid profile</measure>
    <time_frame>baseline - 3 months</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">100</enrollment>
  <condition>Obesity</condition>
  <arm_group>
    <arm_group_label>treament</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>herbalife protein shake along with exercise</description>
  </arm_group>
  <arm_group>
    <arm_group_label>control</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>diet and exercise only</description>
  </arm_group>
  <intervention>
    <intervention_type>Dietary Supplement</intervention_type>
    <intervention_name>herbalife protein shake</intervention_name>
    <arm_group_label>treament</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Subjects aged between 21 -65 years

          2. Subjects with BMI &gt; 23 Kg/m2

        Exclusion Criteria:

          -  Inclusion Criteria:

               1. Subjects aged between 21 -65 years

               2. Subjects with BMI &gt; 23 Kg/m2

        Exclusion Criteria:

          1. Diabetes (type 1 and type 2)

          2. Known or documented coronary heart disease (CHD) (including ECG consistent with prior
             myocardial infraction), cerebrovascular accident (including transient ischemic
             attack), peripheral vascular disease (including symptoms of claudication)

          3. Angina or other chest pain that may indicate CHD by history

          4. Clinically significant neoplastic, cardiovascular, hepatic, renal, metabolic,
             endocrine (untreated or unstable), or psychiatric (untreated or unstable) by history

          5. Medications: Lipid lowering therapy, daily NSAID or greater than 325 mg ASA (PRN use
             ok), clopidogrel (or equivalent), Coumadin, other investigational drugs within 30 days
             of study entry

          6. Pregnancy or planning pregnancy during the study period by history

          7. Uncontrolled hypertension

          8. Uncontrolled hypothyroidism

          9. Sensitivity or allergy to product by history

         10. Subjects who had undergone bypass procedure

         11. Any debilitating disease such as tuberculosis, HIV by history .

         12. Unwillingness to give written informed consent for participation in the study
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>Fortis-C-DOC Centre of Excellence for Diabetes, Metabolic Diseases and Endocrinology</name>
      <address>
        <city>Delhi</city>
        <country>India</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>India</country>
  </location_countries>
  <verification_date>February 2015</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>May 20, 2014</study_first_submitted>
  <study_first_submitted_qc>May 20, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 22, 2014</study_first_posted>
  <last_update_submitted>February 10, 2015</last_update_submitted>
  <last_update_submitted_qc>February 10, 2015</last_update_submitted_qc>
  <last_update_posted type="Estimate">February 11, 2015</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Diabetes Foundation, India</investigator_affiliation>
    <investigator_full_name>Dr Anoop Misra</investigator_full_name>
    <investigator_title>Director</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Weight Loss</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

